Get the Stockscreener App
4.285
1.06%
0.045
After Hours:
4.29
0.005
+0.12%
Compass Therapeutics Inc stock is traded at $4.285, with a volume of 1.58M.
It is up +1.06% in the last 24 hours and up +20.03% over the past month.
Compass Therapeutics Inc is a clinical-stage biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat solid tumors and hematological malignancies. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to drug the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-IO Bispecific, and CTX-8371.
See More
Previous Close:
$4.24
Open:
$4.25
24h Volume:
1.58M
Relative Volume:
1.19
Market Cap:
$592.54M
Revenue:
-
Net Income/Loss:
$-45.44M
P/E Ratio:
-12.24
EPS:
-0.35
Net Cash Flow:
$-42.28M
1W Performance:
+16.76%
1M Performance:
+20.03%
6M Performance:
+152.80%
1Y Performance:
+116.41%
1-Day Range:
$4.06
$4.395
1-Week Range:
$3.52
$4.395
52-Week Range:
$1.27
$4.395
Compass Therapeutics Inc Stock (CMPX) Company Profile
Name
Compass Therapeutics Inc
Sector
Industry
Phone
617-500-8099
Address
80 GUEST STREET, BOSTON
Compare CMPX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CMPX
Compass Therapeutics Inc
|
4.285 | 727.47M | 0 | -45.44M | -42.28M | -0.35 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.37 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.95 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
557.73 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
799.56 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
327.03 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Compass Therapeutics Inc Stock (CMPX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-01-25 | Resumed | Raymond James | Outperform |
| Apr-02-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Feb-24-25 | Initiated | Guggenheim | Buy |
| Feb-19-25 | Initiated | Piper Sandler | Overweight |
| Dec-23-24 | Initiated | D. Boral Capital | Buy |
| Nov-15-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Sep-16-24 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
| Jan-31-23 | Initiated | Jefferies | Buy |
| Jan-27-23 | Initiated | Stifel | Buy |
| May-23-22 | Resumed | H.C. Wainwright | Buy |
| Mar-15-22 | Initiated | Ladenburg Thalmann | Buy |
| Jan-19-22 | Initiated | B. Riley Securities | Buy |
| Dec-22-21 | Initiated | Raymond James | Outperform |
| Dec-20-21 | Initiated | SVB Leerink | Outperform |
| Dec-15-21 | Initiated | Wedbush | Outperform |
View All
Compass Therapeutics Inc Stock (CMPX) Latest News
Is Compass Therapeutics Inc. stock reversal real or fakeJuly 2025 Fed Impact & High Yield Equity Trading Tips - newser.com
Using fundamentals and technicals on Compass Therapeutics Inc.Fed Meeting & Real-Time Volume Analysis Alerts - newser.com
Risk adjusted return profile for Compass Therapeutics Inc. analyzedWeekly Trading Summary & Real-Time Volume Trigger Notifications - newser.com
How to monitor Compass Therapeutics Inc. with trend dashboards2025 Big Picture & Real-Time Volume Surge Alerts - newser.com
Why Compass Therapeutics Inc. stock is seen as undervalued2025 Trade Ideas & Real-Time Stock Price Movement Reports - newser.com
Why Compass Therapeutics, Inc. (CMPX) is Skyrocketing So Far in 2025 - MSN
Visual trend scoring systems applied to Compass Therapeutics Inc.July 2025 Outlook & Intraday High Probability Setup Alerts - newser.com
Certain Common Stock of Compass Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 12-OCT-2025. - MarketScreener
Compass Therapeutics (NASDAQ:CMPX) Shares Up 4.8%Here's Why - MarketBeat
Compass Therapeutics (NASDAQ:CMPX) Reaches New 1-Year HighHere's What Happened - MarketBeat
What is Lifesci Capital's Estimate for CMPX Q3 Earnings? - MarketBeat
Key metrics from Compass Therapeutics Inc.’s quarterly dataIndex Update & Precise Buy Zone Tips - newser.com
Compass Therapeutics' (CMPX) "Sell (D-)" Rating Reiterated at Weiss Ratings - MarketBeat
Published on: 2025-10-09 04:14:15 - newser.com
Regression analysis insights on Compass Therapeutics Inc. performanceQuarterly Portfolio Summary & Free Low Drawdown Momentum Trade Ideas - newser.com
How to use a screener to detect Compass Therapeutics Inc. breakoutsWeekly Trade Report & Verified Chart Pattern Signals - newser.com
Will Compass Therapeutics Inc. stock outperform Nasdaq indexForecast Cut & Technical Pattern Recognition Alerts - newser.com
Compass Therapeutics (NASDAQ:CMPX) Coverage Initiated by Analysts at Lifesci Capital - Defense World
Compass Therapeutics (NASDAQ:CMPX) Now Covered by Lifesci Capital - MarketBeat
LifeSci Capital Initiates Coverage of Compass Therapeutics (CMPX) with Outperform Recommendation - Nasdaq
Backtesting results for Compass Therapeutics Inc. trading strategies2025 Market Overview & Safe Entry Momentum Stock Tips - newser.com
Will breakout in Compass Therapeutics Inc. lead to full recoveryPortfolio Gains Report & Comprehensive Market Scan Reports - newser.com
Compass Therapeutics Inc. stock volume spike explainedEntry Point & Community Trade Idea Sharing Platform - newser.com
Forecasting Compass Therapeutics Inc. price range with options dataTrade Volume Report & Reliable Intraday Trade Alerts - newser.com
Will Compass Therapeutics Inc. stock return to pre crisis levelsRate Cut & Long-Term Capital Growth Strategies - newser.com
What analysts say about Compass Therapeutics Inc stockContrarian Investment Ideas & You’ll Regret Not Buying These Early - earlytimes.in
Compass Therapeutics Inc Stock Analysis and ForecastTrading Volume Trends & Free Tap Rapid Wealth - earlytimes.in
Is Compass Therapeutics Inc a good long term investmentGlobal Trade Effects & Free Stock Trading Workshops - Early Times
Compass Therapeutics Inc Stock (CMPX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Compass Therapeutics Inc Stock (CMPX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| GORDON CARL L | Director |
Apr 09 '25 |
Sale |
1.59 |
3,571,428 |
5,678,571 |
0 |
| ORBIMED ADVISORS LLC | Director |
Apr 09 '25 |
Sale |
1.59 |
3,571,428 |
5,678,571 |
0 |
1.11%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):